mTOR inhibitors for treatment of low-risk prostate cancer.
Liss MA, Rickborn L, DiGiovanni J, Bacich D, DeGraffenried LA, Parihar M, Thompson IM, Sharp ZD.
Liss MA, et al.
Med Hypotheses. 2018 Aug;117:63-68. doi: 10.1016/j.mehy.2018.06.004. Epub 2018 Jun 5.
Med Hypotheses. 2018.
PMID: 30077200
Free PMC article.